用 N-丙炔基甘氨酸对 HYPDH/PRODH2 进行治疗靶向治疗为高草酸尿症治疗提供了机会。
Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity.
机构信息
Buck Institute for Research on Aging, Novato, CA, USA.
Departments of Biochemistry and Chemistry, University of Missouri, Columbia, MO, USA.
出版信息
Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870(1):166848. doi: 10.1016/j.bbadis.2023.166848. Epub 2023 Aug 14.
Abstract
N-propargylglycine prevents 4-hydroxyproline catabolism in mouse liver and kidney. N-propargylglycine is a novel suicide inhibitor of PRODH2 and induces mitochondrial degradation of PRODH2. PRODH2 is selectively expressed in liver and kidney and contributes to primary hyperoxaluria (PH). Preclinical evaluation of N-propargylglycine efficacy as a new PH therapeutic is warranted.
摘要
N-丙炔基甘氨酸可防止小鼠肝、肾中 4-羟脯氨酸的分解代谢。N-丙炔基甘氨酸是 PRODH2 的新型自杀抑制剂，并诱导 PRODH2 的线粒体降解。PRODH2 选择性地在肝和肾中表达，并有助于原发性高草酸尿症（PH）。需要对 N-丙炔基甘氨酸作为新型 PH 治疗药物的疗效进行临床前评估。
相似文献
1
Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity.
Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870(1):166848. doi: 10.1016/j.bbadis.2023.166848. Epub 2023 Aug 14.
2
The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.
Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165633. doi: 10.1016/j.bbadis.2019.165633. Epub 2019 Dec 7.
3
Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria.
Biochem J. 2015 Mar 1;466(2):273-81. doi: 10.1042/BJ20141159.
4
Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria.
Am J Physiol Gastrointest Liver Physiol. 2012 Mar 15;302(6):G637-43. doi: 10.1152/ajpgi.00331.2011. Epub 2011 Dec 29.
5
Brain transcriptomic, metabolic and mitohormesis properties associated with N-propargylglycine treatment: A prevention strategy against neurodegeneration.
Brain Res. 2024 Mar 1;1826:148733. doi: 10.1016/j.brainres.2023.148733. Epub 2023 Dec 20.
6
A new metabolite of propargylglycine, gamma-glutamylpropargylglycylglycine, in liver of D,L-propargylglycine-administered rats.
Biochim Biophys Acta. 1997 Mar 15;1334(2-3):240-6. doi: 10.1016/s0304-4165(96)00100-6.
7
N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties.
Amino Acids. 2021 Dec;53(12):1927-1939. doi: 10.1007/s00726-021-03012-9. Epub 2021 Jun 5.
8
Genetic cause and prevalence of hydroxyprolinemia.
J Inherit Metab Dis. 2016 Sep;39(5):625-632. doi: 10.1007/s10545-016-9940-2. Epub 2016 May 2.
9
Formation of gamma-glutamylpropargylglycylglycine from propargylglycine in human blood and erythrocytes.
Acta Med Okayama. 1999 Feb;53(1):19-25. doi: 10.18926/AMO/31648.
10
Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.
Biochim Biophys Acta. 2016 Feb;1862(2):233-9. doi: 10.1016/j.bbadis.2015.12.001. Epub 2015 Dec 2.
引用本文的文献
1
Biochemical, structural, and cellular characterization of S-but-3-yn-2-ylglycine as a mechanism-based covalent inactivator of the flavoenzyme proline dehydrogenase.
Arch Biochem Biophys. 2025 Mar;765:110319. doi: 10.1016/j.abb.2025.110319. Epub 2025 Jan 25.
2
Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.
Kidney Int Rep. 2024 Sep 1;9(11):3083-3096. doi: 10.1016/j.ekir.2024.08.031. eCollection 2024 Nov.
3
Noncovalent Inhibition and Covalent Inactivation of Proline Dehydrogenase by Analogs of -Propargylglycine.
Biochemistry. 2024 Nov 5;63(21):2855-2867. doi: 10.1021/acs.biochem.4c00429. Epub 2024 Oct 22.
本文引用的文献
1
N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties.
Amino Acids. 2021 Dec;53(12):1927-1939. doi: 10.1007/s00726-021-03012-9. Epub 2021 Jun 5.
2
MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights.
Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396. doi: 10.1093/nar/gkab382.
3
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712.
4
Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias.
J Pers Med. 2021 Jan 27;11(2):74. doi: 10.3390/jpm11020074.
5
22q11.2 deletion syndrome and schizophrenia.
Acta Biochim Biophys Sin (Shanghai). 2020 Dec 11;52(11):1181-1190. doi: 10.1093/abbs/gmaa113.
6
Skyline for Small Molecules: A Unifying Software Package for Quantitative Metabolomics.
J Proteome Res. 2020 Apr 3;19(4):1447-1458. doi: 10.1021/acs.jproteome.9b00640. Epub 2020 Mar 26.
7
Future treatments for hyperoxaluria.
Curr Opin Urol. 2020 Mar;30(2):171-176. doi: 10.1097/MOU.0000000000000709.
8
The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.
Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165633. doi: 10.1016/j.bbadis.2019.165633. Epub 2019 Dec 7.
9
Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition.
Mol Cancer Ther. 2019 Aug;18(8):1374-1385. doi: 10.1158/1535-7163.MCT-18-1323. Epub 2019 Jun 12.
10
Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria.
J Am Soc Nephrol. 2018 Jun;29(6):1615-1623. doi: 10.1681/ASN.2017040390. Epub 2018 Mar 27.
Zotero 插件